Scholarlink

Study design <p>Systematic Review.</p> Objectives <p>To thoroughly assess the existing literature regarding the impact of anti-RhoA/ROCK agents or procedures on functional recovery in animal models of SCI.</p> Setting <p>Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences.</p> Methods <p>A comprehensive search was conducted in Ovid MEDLINE, Embase, Scopus, and Web of Science Core Collection utilizing a combination of keywords. All in-vivo animal studies of acute or chronic SCI that evaluated the pharmacological effects of Rho/ROCK inhibitors in English literature were included in this study.</p> Results <p>Totally, 2320 articles were identified, of which, 60 papers were included for further analysis. A total of 47 (78%) studies were conducted merely on rats, 9 (15%) on mice, 3 (5%) used both, and the remaining used other animals. Y-27632, Fasudil, C3 Transferase and its derivatives (C<sub>3</sub>-05/PEP-C<sub>3</sub>/CT04/C<sub>3</sub>bot154–182/C<sub>3</sub>bot26mer(156–181)), Ibuprofen, Electroacupuncture (EA), SiRhoA, miR-133b, miR-135-5p, miR-381, miR-30b, Statins, 17β-estradiol, β-elemene, Lentivirus-mediated PGC-1a, Repulsive guidance molecule (RGMa), Local profound hypothermia, Jisuikang (JSK), Hyperbaric oxygen (HBO), Lv-shRhoA (Notch-1 inhibitor), Anti-Ryk antibody, LINGO-antagonist, BA-210, p21Cip1/WAF1, ORL-1 antagonist, Epigallocatechin‐3‐gallate (EGCG), Tamsulosin, AAV.ULK1.DN, and Indomethacin were the 28 reported agents/procedures with anti-RhoA/ROCK effects. The pooled SMD for BBB scores was 0.41 (<i>p</i> = 0.048) in the first week, 0.85 (<i>p</i> &lt; 0.001) in the second week, 1.22 (<i>p</i> = 0.010) in the third week, and 1.53 (<i>p</i> = 0.001) in the fourth week.</p> Conclusion <p>Of the 28 identified anti-RhoA/ROCK agents, all but two (C<sub>3</sub>bot and its derivatives and EGCG) demonstrated promising results. The results of the meta-analysis cautiously indicate a significant increase in BBB scores over time after SCI.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The potential role of RhoA/ROCK-inhibition on locomotor recovery after spinal cord injury: a systematic review of in-vivo studies

  • 期刊论文

  • 发表日期：

    2025年2月16日

查看全文
  • Armin Khavandegar,
  • Negar Sadat Ahmadi,
  • Maryam Alsadat Mousavi,
  • Zahra Ramezani,
  • Elaheh Khodadoust,
  • Mahgol Sadat Hasan Zadeh Tabatabaei,
  • Zahra Hasanpour Segherlou,
  • Arman Zeinaddini-Meymand,
  • Fatemeh Nasehi,
  • Maral Moafi,
  • Kimia RayatSanati,
  • Rasool Masoomi,
  • Sorour Hamidi,
  • Soheila Pourkhodadad,
  • Vafa Rahimi-Movaghar

摘要

Study design

Systematic Review.

Objectives

To thoroughly assess the existing literature regarding the impact of anti-RhoA/ROCK agents or procedures on functional recovery in animal models of SCI.

Setting

Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences.

Methods

A comprehensive search was conducted in Ovid MEDLINE, Embase, Scopus, and Web of Science Core Collection utilizing a combination of keywords. All in-vivo animal studies of acute or chronic SCI that evaluated the pharmacological effects of Rho/ROCK inhibitors in English literature were included in this study.

Results

Totally, 2320 articles were identified, of which, 60 papers were included for further analysis. A total of 47 (78%) studies were conducted merely on rats, 9 (15%) on mice, 3 (5%) used both, and the remaining used other animals. Y-27632, Fasudil, C3 Transferase and its derivatives (C3-05/PEP-C3/CT04/C3bot154–182/C3bot26mer(156–181)), Ibuprofen, Electroacupuncture (EA), SiRhoA, miR-133b, miR-135-5p, miR-381, miR-30b, Statins, 17β-estradiol, β-elemene, Lentivirus-mediated PGC-1a, Repulsive guidance molecule (RGMa), Local profound hypothermia, Jisuikang (JSK), Hyperbaric oxygen (HBO), Lv-shRhoA (Notch-1 inhibitor), Anti-Ryk antibody, LINGO-antagonist, BA-210, p21Cip1/WAF1, ORL-1 antagonist, Epigallocatechin‐3‐gallate (EGCG), Tamsulosin, AAV.ULK1.DN, and Indomethacin were the 28 reported agents/procedures with anti-RhoA/ROCK effects. The pooled SMD for BBB scores was 0.41 (p = 0.048) in the first week, 0.85 (p < 0.001) in the second week, 1.22 (p = 0.010) in the third week, and 1.53 (p = 0.001) in the fourth week.

Conclusion

Of the 28 identified anti-RhoA/ROCK agents, all but two (C3bot and its derivatives and EGCG) demonstrated promising results. The results of the meta-analysis cautiously indicate a significant increase in BBB scores over time after SCI.